logo-loader
viewNetscientific PLC

NetScientific to delist from AIM and become a private company following strategic review

The firm said that it had concluded following the review that a revised strategy was required to reduce its central functions and costs “significantly” so as much of its remaining cash as possible could be allocated to its portfolio companies

Scientist
NetScientific invests in development-stage medical and healthcare businesses

NetScientific PLC (LON:NSCI) has said it is looking to delist from AIM and re-register as a private company following a strategic review into its operations.

The firm, which invests in development-stage medical and healthcare businesses, said that it had concluded following the review that a revised strategy was required to reduce its central functions and costs “significantly” to enable as much of its remaining cash as possible be allocated to its portfolio companies.

READ: NetScientific says continuing to assess all remaining strategic options after closing formal sale process​

The company also said it had failed to generate any interest in a possible sale or to elicit and offers for the firms in its portfolio, adding that its cash resources as of 31 December were £3.3mln.

Shares were down 44% at 4.5p.​​

Quick facts: Netscientific PLC

Price: 6.54 GBX

AIM:NSCI
Market: AIM
Market Cap: £5.14 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Netscientific PLC named herein, including the promotion by the Company of Netscientific PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: ANGLE reports positive data from Parsortix FDA clinical study

Top stories from the Proactive Investors UK newsroom: ANGLE PLC (LON:AGL) has received positive results from its Parsortix FDA clinical study for metastatic breast cancer. The 400-subject clinical study will support an application for Class II regulatory clearance for Parsortix in the...

on 31/5/19

2 min read